-
公开(公告)号：US20190048064A1
公开(公告)日：2019-02-14
申请号：US16079165
申请日：2017-02-24
发明人： Gregg WALLIS , Jamie ASHBY , Stephen HARDING
摘要： The invention provides an immunoassay kit providing an immunoassay kit comprising one or more analyte specific antibodies or fragments thereof, characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the analyte- specific antibodies or fragments thereof.
-
公开(公告)号：US20150024416A1
公开(公告)日：2015-01-22
申请号：US14380074
申请日：2013-02-15
发明人： Stephen Harding , Richard Hughes , Anne Bevins , Richard Keir , Michael Chappell , Neil Evans , Colin Hutchinson
IPC分类号： G01N33/68
CPC分类号： G01N33/6857 , G01N2800/50
摘要： The invention provides a method of estimating free light chain production (FLC) in a subject comprising (i) determining an amount of FLC in a sample from the subject; and (ii) correcting the amount of FLC in the sample for FLC cleared from the source of the sample by glomerular filtration and by reticuloendothelial (RE) clearance.
摘要翻译： 本发明提供一种估计受试者中游离轻链产生（FLC）的方法，包括（i）确定来自受试者的样品中FLC的量; 和（ii）校正通过肾小球滤过和网状内皮（RE）清除从样品来源清除的FLC样品中FLC的量。
-
公开(公告)号：US20230391851A1
公开(公告)日：2023-12-07
申请号：US18454967
申请日：2023-08-24
发明人： Gregg Wallis , Jamie Ashby , Stephen Harding
CPC分类号： C07K16/065 , G01N33/6854 , C07K16/00 , G01N33/6857 , A61K47/6877 , A61K51/1087 , A61K51/1093 , C07K2317/94 , A61K2123/00 , C07K2317/24 , C07K2317/52 , C07K2317/54 , C07K2317/624
摘要： A method for analyzing protein(s) in a sample using an immunoassay kit includes creating protein-reducing and/or protein-denaturing conditions by contacting the sample with a reducing and/or denaturing agent provided in the immunoassay kit, to provide a partially or fully denatured protein population. One or both of a presence and an amount of one or more protein-associated analytes are determined under the created protein-reducing and/or protein-denaturing conditions by contacting the partially or fully denatured protein population with one or more specific antibodies or binding fragments thereof provided in the immunoassay kit. The one or more specific antibodies or binding fragments thereof include one or more chemically-introduced non-disulfide cross-links between at least one heavy chain or binding fragment thereof and at least one light chain or binding fragment thereof.
-
公开(公告)号：US20190094239A1
公开(公告)日：2019-03-28
申请号：US16078986
申请日：2017-02-24
发明人： David L. MURRAY , Stephen HARDING , David R. BARNIDGE , Gregg WALLIS , John MILLS , Jamie ASHBY
摘要： An anti-immunoglobulin specific antibody (or fragment thereof), characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the antibody or fragment thereof. A method purifying an anti-immunoglobulin specific antibody (or fragment thereof), characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the antibody or fragment thereof. A method of quantifying an amount of a subject analyte, or a fragment of an analyte in a sample from the subject comprising: (i) adding to the sample a predetermined amount of one or more control analytes or fragments thereof, which are distinguishable from the equivalent subject analyte or fragment; (ii) measuring the relative amount of the subject analyte or fragment and the amount of the control analyte or fragment in the sample; and (iii) comparing the relative amount of subject analyte or fragment to the relative amount of control analyte or fragment, to quantify the amount of analyte or fragment in the original subject sample.
-
公开(公告)号：US20150051839A1
公开(公告)日：2015-02-19
申请号：US14383147
申请日：2013-03-06
发明人： Stephen Harding , Richard Hughes , Hugh Carr-Smith
CPC分类号： G01N33/6857 , G01N2800/22 , G16H50/30
摘要： The invention provides a method for characterising a plasma cell associated disease in a patient comprising: (i) providing at least one sample from the patient; (ii) determining in the sample(s) two or more of; (a) the κ:λ free light chain (FLC) ratio; (b) the ratio of κ light chains bound to a class of heavy chain:λ light chain bound to the same class of heavy chain (HLCκ:HLC λ ratio); (c) the total amount of FLC in the samples and (d) the total amount of κ light chains bound to the heavy chain class plus λ light chains bound to the same heavy chain class (total HLC); (iii) comparing each ratio or amount from (a) (b), (c) and/or (d) to predetermined values and assigning a score to each amount or ratio; and (iv) using the scores to characterise the plasma cell associated disease. Apparatus configured to carry out the method of the invention are also provided. The invention also provides a kit comprising, in combination, (i) anti-κ FLC specific and anti-λ FLC specific antibodies or fragments thereof and (ii) anti-κ heavy chain class specific and anti-λ heavy chain class specific antibodies or fragments thereof, optionally mixed together.
摘要翻译： 本发明提供了一种用于表征患者中血浆细胞相关疾病的方法，包括：（i）从患者提供至少一种样品; （ii）在样本中确定两个或更多个样本; （a）＆kgr;：λ自由轻链（FLC）比; （b）比率＆kgr; 轻链与一类重链结合：λ轻链与同一类重链结合（HLC＆Kgr：HLCλ比）; （c）样品中FLC的总量和（d）总量＆kgr; 绑定到重链类的轻链加上与相同重链类（总HLC）结合的λ轻链; （iii）将（a）（b），（c）和/或（d）的每个比例或量与预定值进行比较，并将分数分配给每个量或比率; 和（iv）使用分数来表征浆细胞相关疾病。 还提供了用于实现本发明的方法的设备。 本发明还提供了一种试剂盒，其组合包含（i）抗 - FLC特异性抗体和抗-λFLC特异性抗体或其片段，和（ii）抗 - 重链类特异性和抗λ重链类特异性抗体或其片段，任选地混合在一起。
-
公开(公告)号：US20230333107A1
公开(公告)日：2023-10-19
申请号：US17927178
申请日：2021-05-20
发明人： Stephen HARDING , David BARNIDGE , Charles DE ROHAN , Richard HUGHES , Sabah PASHA , Simon NORTH , Roshani PATEL , Gregg WALLIS
IPC分类号： G01N33/569 , G01N33/68
CPC分类号： G01N33/56983 , G01N33/6851 , G01N2333/165 , G01N2469/20
摘要： This invention provides a method of identifying or characterising an immune response in a subject comprising: (a) contacting a sample containing immunoglobulins from the subject with at least one antigen immobilised on a support; (b) washing unbound, non-antigen specific immunoglobulins from the support to leave antigen-specific immunoglobulins bound to the antigen on the support; (c) optionally eluting the antigen-specific immunoglobulins from the antigen on the support; and (d) subjecting the antigen-specific immunoglobulins to mass spectrometry to identify two or more different antigen specific immunoglobulin classes, subclasses and/or light chain types.
-
公开(公告)号：US20200096520A1
公开(公告)日：2020-03-26
申请号：US16615814
申请日：2018-05-23
摘要： The application provides a method of identifying or monitoring a plasma cell associated disease, comprising purifying immunoglobulin free light chains (FLCs) from a sample from a subject with anti-FLC specific antibodies or fragments thereof and subjecting the purified sample to a mass spectrometry technique to identify the presence of one or more peaks corresponding to one or more monoclonal FLCs in the sample.
-
公开(公告)号：US20150173685A1
公开(公告)日：2015-06-25
申请号：US14415884
申请日：2013-07-10
发明人： Richard Hughes , Stephen Harding
CPC分类号： A61B5/7275 , A61B5/02055 , A61B5/021 , A61B5/024 , A61B5/0816 , A61B5/14542 , A61B5/165 , A61B5/208 , A61B5/4824 , A61B2505/01 , A61B2505/03 , G01N33/6857 , G01N33/6893 , G01N2333/47 , G01N2333/76 , G01N2800/56
摘要： The application discloses a method of determining the severity of symptoms in a patient comprising (i) producing a triage score, such as an early warning score (EWS) modified early warning score (MEWS), paediatric early warning score (PEWS), NHS early warning score (NEWS), simple clinical score (SCS), rapid emergency score (REMS) or mortality in emergency department sepsis score for the patient, (ii) measuring an amount of free light chains (FLC), preferably combined free light chains (cFLC), in a sample from the patient, and (iii) using the triage score and the amount of FLC measured to assess the severity of symptoms in the patient. This also allows patients to be triaged to provide better treatment of them.
摘要翻译： 该应用公开了一种确定患者症状严重程度的方法，包括（i）产生分类评分，例如早期预警评分（EWS）修改的早期预警评分（MEWS），儿科早期预警评分（PEWS），早期NHS 警告评分（NEWS），简单临床评分（SCS），快速紧急评分（REMS）或患者急诊部败血症评分死亡率，（ii）测量游离轻链（FLC）的量，优选组合游离轻链 cFLC），以及（iii）使用分类评分和测量的FLC量来评估患者症状的严重程度。 这也使患者能够被分类，以更好地治疗他们。
-
公开(公告)号：US20230080943A1
公开(公告)日：2023-03-16
申请号：US17990554
申请日：2022-11-18
发明人： Gregg WALLIS , Stephen HARDING , Richard HUGHES
摘要： The application provides a method of identifying or monitoring a plasma cell associated disease, comprising purifying immunoglobulin free light chains (FLCs) from a sample from a subject with anti-FLC specific antibodies or fragments thereof and subjecting the purified sample to a mass spectrometry technique to identify the presence of one or more peaks corresponding to one or more monoclonal FLCs in the sample.
-
公开(公告)号：US20220252613A1
公开(公告)日：2022-08-11
申请号：US17629747
申请日：2020-07-23
发明人： Stephen HARDING , Gregg WALLIS , Jamie ASHBY , Nia MARROTT , Simon NORTH
摘要： An elution buffer for eluting one or more predetermined analytes from one or more analyte-specific antibodies or fragments thereof or for eluting one or more predetermined antibodies or fragments from a target antigen, wherein: the elution buffer has a pH of 1 to 5; and the elution buffer comprises a predetermined amount of an acid stable mass spectrometry ionisation control protein. The use of the elution buffer in the detection and quantifying of analytes, for example by mass spectrometry is also described.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.014 秒)
